Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1-20 (Cancelled)

- 21. (Currently amended) A transgenic mouse whose genome comprises a hetrozygous disruption in a serine protease gene comprising SEQ ID NO:1, wherein <a href="mating of such mice results in embryonic lethality of the embryos having a homozygous disruption in said genewhere the disruption is heterozygous, and wherein, upon breeding with a second transgenic mouse whose genome comprises a disruption in the serine protease gene comprising SEQ ID NO:1, the transgenic mouse produces a transgenic mouse having a homozygous disruption in the serine protease gene comprising SEQ ID NO:1 and exhibiting a lethality during embryonic development.
- 22. (Currently amended) The transgenic mouse of claim 21, wherein the <u>embryonic</u> lethality occurs between about 12.5 and 14.5 days of embryonic growth.
- 23. (Currently amended) A method of producing a-the transgenic mouse of claim

 21 whose genome comprises a disruption in a serine protease gene comprising SEQ

 ID NO:1, the method comprising:
 - (a) providing a mouse embryonic stem cell comprising a disruption in the serine protease gene comprising SEQ ID NO:1;
 - (b) introducing the mouse embryonic stem cell into a mouse blastocyst;
 - (c) introducing the mouse blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and
 - (d) breeding two chimeric mice to produce the transgenic mouse, wherein where the disruption is heterozygous, the transgenic mouse, upon breeding, produces a transgenic mouse whose genome comprises a homozygous disruption in the serine protease gene comprising SEQ ID NO:1 exhibiting a lethality during embryonic development.

Claims 24, 25 (Canceled).